Studied for effect of delayed enucleation on mortality

Slides:

Advertisements

Similar presentations

Highligths in management of gastrointestinal cancer April 11, 2008 CONTROVERSIES IN THE CONTROVERSIES IN THE ADJUVANT THERAPY ADJUVANT THERAPY OF GASTRIC.

Advertisements

Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in.

Carboplatin Not Inferior to Radiation as Adjuvant Therapy for Stage I Seminoma Slideset on: Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose.

Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.

Carolinas Medical Center, Charlotte, NC Website:

Immunotherapy with CD19 CAR redirected T-cells for high risk, relapsed paediatric CD19+ acute lymphoblastic leukaemia (ALL) and other haematological malignancies.

ACCORD Microvascular Outcomes

Survival After Single Versus Bilateral Lung Transplantation for High-Risk Patients With Pulmonary Fibrosis Eric S. Weiss, MD, MPH, Jeremiah G. Allen,

SD Walter MD1, T Mahten MD2, JW Harbour MD1,3

Figure 2. A consort diagram showing the flowchart of the trial

The Role of Radical Prostatectomy and Radiotherapy in Treatment of Locally Advanced Prostate Cancer: A Systematic Review and Meta-Analysis Urol Int 2017;99:

Clinical outcome after SVR: Veterans Affairs

Pulmonary Hypertension Is Associated with Mortality and Cardiovascular Events in Chronic Kidney Disease Patients Am J Nephrol 2017;45: DOI: /

Volume 66, Issue 1, Pages (July 2004)

LUCIE Localised Urothelial Carcinoma Immuno-oncology Evaluation Randomised Phase II trial, evaluating safety and efficacy of a combination therapy of.

The presence of lung metastases does not influence survival in liver metastatic colorectal cancer Jennie Engstrand1, Henrik Nilsson1, Cecilia Strömberg2,

Consort Diagram 600 pts with 644 eyes accessed for eligibility

The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk.

Consort Diagram 600 pts with 644 eyes accessed for eligibility

High retinoblastoma (RB) expression is prevalent in human pancreatic ductal adenocarcinoma (PDA) and is of prognostic relevance in independent cohorts.

Supplemental Figure 1: Kaplan-Meier Curves of overall survival based on clinical stage at presentation and treatment modality Kaplan-Meier analyses depicting.

Early Systolic Blood Pressure Changes in Incident Hemodialysis Patients Are Associated with Mortality in the First Year Kidney Blood Press Res 2012;35:663–670.

Shidan Wang, BS, Lin Yang, MD, Bo Ci, BS, Matthew Maclean, BS, David E

Elliot Wakeam, MD, MPH, Meredith Giuliani, MBBS, MEd, Natasha B

Diabetes Journal Club March 17, 2011

Durability of the balloon-expandable covered versus bare-metal stents in the Covered versus Balloon Expandable Stent Trial (COBEST) for the treatment.

Frequency of cancer in patients operated on for acute peripheral arterial thrombosis and the impact on prognosis Chalotte Winther Nicolajsen, MD, Maja.

The Impact of Peripheral Vascular Disease on Long-Term Survival After Coronary Artery Bypass Graft Surgery Danny Chu, MD, Faisal G. Bakaeen, MD, Xing.

A B Yeom Supplementary Fig.2

Assessed for eligibility (N = 600)

Factors predicting patterns of recurrence after resection of N1 non-small cell lung carcinoma Timothy E Sawyer, MD, James A Bonner, MD, Perry M Gould,

One-year clinical outcomes in older patients with non-ST elevation acute coronary syndrome undergoing coronary angiography: An analysis of the ICON1 study

Anthony Lemaire, MD, William R

Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial Michael J. Mack, MD.

The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy Arya Amini, BA, Arlene.

LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.

Shawn L Fultz, MD MPH VACS Scientific Meeting, Feb 2004

Age-Dependent Gender Disparities in Post Lung Transplant Survival Among Patients With Idiopathic Pulmonary Fibrosis Shahid I. Sheikh, MD, Don Hayes,

Radical Lymph Node Dissection in Primary Esophagectomy for Esophageal Squamous Cell Carcinoma Chen-Sung Lin, MD, PhD, Chih-Tao Cheng, MD, DrPH, Chao-Yu.

PRIMARY EXTREMITY STS: MULTIMODAL APPROACH MAY HAVE IMPROVED SURVIVAL

Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations Yelena Y.

Interaction of Donor and Recipient Age: Do Older Heart Transplant Recipients Require Younger Hearts? Malini Daniel, MD, Carol Chen, MD, Jennifer Chung,

Current efficacy of open and endovascular interventions for advanced superficial femoral artery occlusive disease Christopher J. Smolock, MD, Javier.

Survival by time of day of hemodialysis: analysis of United States renal data system dialysis morbidity and mortality waves III/IV Kevin C Abbott, MD,

Retinoblastoma Treated by Chemotherapy and PPV with 5 Years Follow-up

Consort Diagram 600 pts with 644 eyes accessed for eligibility

Stephen R. Broderick, MD, MPHS, Aalok P. Patel, BS, BA, Traves D

James D Luketich, Michael E Burt The Annals of Thoracic Surgery

Antonio V. Sterpetti, MD, Richard D. Schultz, MD, Richard J

Patients Excluded from Study

A I II 1 2 H1 H0 20/ logMAR B F+F C D Figure 1. (A) Pedigree of a family with a unilaterally affected father discovered to be mosaic (H1) for a high.

Studied for effect of delayed enucleation on mortality

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

* * ↨ ↨ * * ↨ ↨ Figure 1: Early awareness of risk for retinoblastoma optimizes therapy and outcomes. This child was examined because his sibling (triplets)

Fig 1A: PPV only (n = 5) Staging EUA Enucleation Systemic chemotherapy

Studied for effect of delayed enucleation on mortality

Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome

Fig. 4 High P-eIF2α expression in human prostate tumors with loss of PTEN function is associated with increased risk of metastasis or death after surgery.

Fig. 3. Improved clinical responses to CD19 CAR-T cell immunotherapy after Cy/Flu lymphodepletion. Improved clinical responses to CD19 CAR-T cell immunotherapy.

Efficacious use of nitinol stents in the femoral and popliteal arteries Todd R Vogel, MD, Larry E Shindelman, MD, Gary B Nackman, MD, Alan M Graham, MD

The Kaplan-Meier curves display the time to event for the primary outcome (A) and total mortality (B) during follow-up from randomization until the end.

A: Incidences of all-cause mortality, coronary artery events, and cerebrovascular events by quartiles of baPWV during the follow-up period. A: Incidences.

Figure S1. A. B. Figure S1. Kaplan-Meier curve of progression-free survival by treatment group in soluble heregulin (HRG)-high population (A) and soluble.

Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.

Impact of Immunotherapy after Resection of Pancreatic Cancer

by Jan J. Cornelissen, and Didier Blaise

Uncovering the Right Sequence

Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.

Avasare et al. Am J Nephrol 2017;45:99-106 (DOI: / )

Presentation transcript:

Studied for effect of delayed enucleation on mortality Eligibility: Intraocular retinoblastoma; no extraocular or metastatic disease at diagnosis (N = 600) Primary exclusion (n = 46) Bilateral advanced RB (n = 44) Died from chemotherapy toxicity (n = 2) Studied for effect of delayed enucleation on mortality (n = 554) IIRC Group D (n = 202) Died from RB metastasis (n = 6) IIRC Group E (n = 352) Died from RB metastasis (n = 16) Secondary exclusion (n = 44) Received < 1 cycle of pre-enucleation chemotherapy (n = 15) Received non-systemic chemotherapy salvage therapy (n = 29) Intra-arterial chemotherapy (n = 18) Pars plana vitrectomy endoresection (n = 6) Plaque radiotherapy (n = 3) Stem cell transplantation (n = 1) Immunotherapy (n = 1) FIG 1. CONSORT diagram. Studied for effect of pre-enucleation systemic chemotherapy on mortality (n = 510) IIRC Group D (n = 177) Died from RB metastasis (n = 4) IIRC Group E (n = 333) Died from RB metastasis (n = 16)

A B Children with IIRC group D eyes Children with IIRC group E eyes < 3.5 months from diagnosis to enucleation < 2 months from diagnosis to enucleation > 3.5 months from diagnosis to enucleation > 2 months from diagnosis to enucleation Log-rank P = .018 Log-rank P = .017 FIG 2. Kaplan-Meier curves of disease-specific survival (DSS) of children with enucleated Groups D and E eyes. (A) DSS of children with group D eyes enucleated < 3.5 months and > 3.5 months from diagnosis. (B) DSS of children with group E eyes enucleated < 2 months and > 2 months from diagnosis. No. at risk < 3.5 months dx to enu 97 93 89 72 20 > 3.5 months dx to enu 105 99 92 66 17 1 No. at risk < 2 months dx to enu 268 227 212 174 68 6 > 2 months dx to enu 84 75 65 56 34 1

Primary enucleation 1 to 3 cycles of pre-enucleation chemotherapy ≥ 4 cycles of pre-enucleation chemotherapy Log-rank P = .031 No. at risk Primary enucleation 214 182 173 139 44 6 1 to 3 cycles of chemotherapy 72 60 55 50 33 ≥ 4 cycles of chemotherapy 47 42 30 20 1 FIG 3. Kaplan-Meier curves and Cox proportional hazard regression model of disease-specific survival of children with enucleated Group E eyes who received primary enucleation, 1 to 3 cycles of pre-enucleation chemotherapy and ≥ 4 cycles of pre-enucleation chemotherapy. Group n Events HR (95% CI) P Primary enucleation 214 8 0.77 (0.16 to 3.61) .74 1 to 3 chemotherapy cycles 72 2 3.35 (1.16 to 9.67) .025 ≥ 4 chemotherapy cycles 47 6

A B Low-risk eyes without pre-enucleation chemotherapy Low-risk eyes without post-enucleation chemotherapy Low-risk eyes with pre-enucleation chemotherapy Low-risk eyes with post-enucleation chemotherapy High-risk eyes without pre-enucleation chemotherapy High-risk eyes without post-enucleation chemotherapy High-risk eyes with pre-enucleation chemotherapy High-risk eyes with post-enucleation chemotherapy Log-rank P < .001 Log-rank P < .001 No. at risk LR eyes w/o chemo 196 176 170 136 41 5 LR eyes w/ chemo 208 191 146 73 2 HR eyes w/o chemo 79 64 59 46 13 1 HR eyes w/ chemo 27 21 14 10 No. at risk LR eyes w/o chemo 291 268 252 197 45 2 LR eyes w/ chemo 151 135 129 114 76 5 HR eyes w/o chemo 15 11 6 3 HR eyes w/ chemo 97 80 71 54 18 1 FIG 4. Kaplan-Meier curves and Cox proportional hazard regression model of disease-specific survival (DSS) of children with enucleated low-risk (LR) and high-risk (HR) eyes (A) DSS of children who received pre-enucleation chemotherapy compare with those who did not. (B) DSS of children who received post-enucleation compare with those who did not. Group n Events HR (95% CI) P LR eyes w/o chemo 196 2 0.94 (0.13 to 6.70) .95 LR eyes w/ chemo 208 HR eyes w/o chemo 79 6 5.21 (1.89 to 14.29) < .001 HR eyes w/ chemo 27 10 Group n Events HR (95% CI) P LR eyes w/o adjuvant chemo 291 4 0.49 (0.054 to 4.35) .52 LR eyes w/ adjuvant chemo 151 1 HR eyes w/o adjuvant chemo 15 7 0.20 (0.074 to 0.52) .001 HR eyes w/ adjuvant chemo 97 10